Key result
Cardiovascular clinical trials historically under-represent women and minority groups, limiting result generalizability.
Answers are grounded in this paper and cite their sources.
Highlights the historical under-representation of racial/ethnic minority groups and women in cardiovascular clinical trials and the resulting limitations on generalizability.
istorically, racial/ethnic minority groups in Western countries are often under-represented in clinical trials, including those evaluating cardiovascular disease.In a large systematic review of clinical trials of acute coronary syndrome, race/ethnicity were only reported in 22% of trials; among those, Black individuals represented only 3.7% of participants without a change from 2001 to 2018, although Hispanic individuals represented only 7.8% of participants but with improvement over time.In addition, women were also significantly under-represented, making up 27% of the clinical trial population, without significant improvement over time. 1 These disparities can limit confidence in clinical trial results, especially the generalizability of findings to individuals not represented in clinical trial populations.
No takes yet. Share an insight, caveat, or question.
Harpreet Singh Bhatia (2026) conducted an editorial in Cardiovascular disease / acute coronary syndrome. Cardiovascular clinical trials historically under-represent women and minority groups, limiting result generalizability.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: